Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells.

Treatment with Cinnamic acid (CINN) of various tumor cells of epithelial and neuroectodermal origin result in dose-dependent growth inhibition following a 3-day exposure. The inhibitory concentrations causing a 50% reduction in tumor-cell proliferation (IC₅₀) are between 1.2 to 4.5 mM. It is also showed that 20 mM Cinnamic acid is needed to cause an IC₅₀ in FS4 cells, i.e. 5 to 20 times more than for tumor cells. In addition to inhibiting tumor-cell proliferation, Cinnamic acid causes morphological changes consistent with melanocyte differentiation. Within 5 days of treatment with 5 mM Cinnamic acid, melanoma 1011 cells appear enlarged with a markedly increased cytoplasm-to-nuclear ratio and well organized cytoskeleton, developed long dendritic processes and became highly melanotic. The change in the capacity of Cinnamic acid -treated melanoma 1011, A375(M) and SKMEL28 cells to degrade and cross tissue barriers is assessed by an in vitro invasion assay using modified Boyden chambers with matrigel-coated filters. After 3 days of continuous treatment with Cinnamic acid, a dose-dependent loss of invasive capacity in 3 tested tumor lines is observed. Treatment with 5 mM Cinnamic acid results in 75-95% loss of invasiveness^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

148.16

C₉H₈O₂

621-82-9

Room temperature in continental US; may vary elsewhere.

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

In Vitro: 

Ethanol : ≥ 50 mg/mL (337.47 mM)

DMSO : 50 mg/mL (337.47 mM; Need ultrasonic)

* “≥” means soluble, but saturation unknown.

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% EtOH    40% PEG300    5% Tween-80    45% saline

  Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (16.87 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

• 2.

  请依序添加每种溶剂： 10% EtOH    90% (20% SBE-β-CD in saline)

  Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (16.87 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% EtOH    90% corn oil

  Solubility: ≥ 2.5 mg/mL (16.87 mM); Clear solution

  此方案可获得 ≥ 2.5 mg/mL (16.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中，混合均匀。

• [1]. Liu L, et al. Cinnamic acid: a natural product with potential use in cancer intervention. Int J Cancer. 1995 Jul 28;62(3):345-50.

The cell lines used, established from human malignant tumors, are A549 (lung cancer); PC3(M), Du145, and LNCaP (prostate cancer); A172, U251 (glioblastoma); and SKMEL28, A375(M), 1011 (melanoma). Growth rates are determined by cell counting. Briefly, 5 X10⁴ cells are plated in each well of a 24-well plate, allowed to attach overnight, and treated with compounds (e.g., Cinnamic acid: 2.5, 5, 10, 20, 30 mM) the following day. Cells are grown for 3 days at 37°C in the presence or absence of the drug, then detached with trypsin/EDTA and counted in a Coulter counter. Viability is determined by Trypan-blue exclusion assay^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Liu L, et al. Cinnamic acid: a natural product with potential use in cancer intervention. Int J Cancer. 1995 Jul 28;62(3):345-50.